Onyx Scientific appoints European Business Development representative
“These are important biotech areas for Onyx Scientific’s services and a local contact as experienced as Enrico will undoubtedly enhance our capabilities in these areas” commented Denise Bowser, Commercial Director at Onyx Scientific.
Enrico has over 24 years experience in drug discovery services and a PhD in Pharmacology/Biochemistry. He is fluent in Italian, English and Spanish.
“In the current Pharma and Biotech environment, Companies are looking more and more for reliable partners for Chemical Research and Development. I'm very pleased to collaborate with Onyx Scientific, a Company that, for many years, have been proving the capability to foresee Market trends and fully respond to the growing and changing demands from many Pharma and Biotech customers in the world.” commented Dr Grassi.
Onyx Scientific Limited is a chemistry Outsourcing specialist that supplies a diverse array of chemistry research and development services to the pharmaceutical and related industries. Onyx Scientific provides contract research, custom synthesis, small-scale cGMP manufacturing, polymorphism, salt selection and other services plus novel fine chemicals based on proprietary technology.
Further information on the appointment or about Onyx Scientific Ltd. can be obtained by contacting Dr. Tony Flinn:
Telephone 0044 (0) 191 516 6 516
Fax 0044 (0) 191 516 6 526
Mobile Telephone: 07712 760231
Sunderland Enterprise Park East
Tyne and Wear
SR5 2TQ, UK.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Onyx Scientific appoints European Business Development representative here
News-ID: 137097 • Views: 876
More Releases from Onyx Scientific Ltd
GMP Synthesis chemistry services organisation, Onyx Scientific, announce increas …
Leading chemistry services organisation, Onyx Scientific Ltd, is pleased to announce an increased demand for its early-phase, GMP synthesis, Investigational New Drug (IND) services for the development of Active Pharmaceutical Ingredients (APIs). “At Onyx we plan for success by focussing on detail” explains CEO Tony Flinn. “Our service driven systems deliver comprehensive chemical route development, efficient raw materials sourcing, thorough analysis and world-class solid-state characterization. We are recognised as the
Custom Synthesis chemistry services CRO, Onyx Scientific, hails the success of i …
Onyx Scientific, a trusted global chemistry services CRO and leading provider of high justified intermediates and APIs for both phase I and phase II clinical studies, hails the success of its world-class solid-state polymorph screening services for the increased demand for its international GMP-compliant Process Development capability. Onyx Scientific specialise in Medicinal Chemistry, Process Development, Custom Synthesis, GMP synthesis and Scale-up, in addition to a comprehensive range of Analytical and
Solid-state chemistry services CRO, Onyx Scientific reports increased demand for …
Experts in the provision of solid-state chemistry services for the pharmaceutical and biotech industries, leading global contract research organisation, Onyx Scientific, is delighted to report increased demand in taking candidate compounds from concept through to process development and scale-up of APIs for Phase I and Phase II clinical studies. “Handling difficult-to-crystallize materials is an art form as well as a science” explains Tony Flinn, CEO, Onyx Scientific. “Inherently complicated, the implications
GMP synthesis chemistry services CRO, Onyx Scientific, reports increased small s …
Internationally renowned, contract research organisation Onyx Scientific, is pleased to announce the continued growth of its small-scale GMP custom synthesis services for development APIs (Active Pharmaceutical Ingredients) Commenting on the growing success of its small-scale GMP synthesis services, CEO, Dr Tony Flinn says “our success is due to open communication and a highly responsive scientific team, who are able to lower the cost of a GMP process by